Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss
A legfontosabb adatok
- Ki végzi
- Eli Lilly and Company
- Hol
- Toronto (Kanada)A helyszín megnézéseMég 3 másik országban, 8 helyszínen
- Azonosító
- Állapot
- Toboroz
- Fázis
- 3. fázis
- Résztvevők
- 48 fő, tervezett
- Kezdés
- 2023. szept. 15.
- Várható befejezés
- 2029. dec.
- A vizsgálat típusa
- Beavatkozással járó, 6 csoport
- A vizsgált kezelések
- AAVAnc80-hOTOF via Akouos Delivery Device
- AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism
- A regiszteradat frissítve
- 2026. szeptember 29.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for people of any age with hearing loss in both ears caused by changes in the otoferlin gene. They get a one-time gene therapy, AAVAnc80-hOTOF, placed in one or both ears.
- Életkor
- Any age, depending on the study group. Some early groups needed people aged 7 to 17 years or at least two years old.
- Nem
- All sexes can join.
- A betegség stádiuma
- Profound (Part A) or severe to profound (Parts B, C and D) sensorineural hearing loss in both ears, measured by ABR (a brain response hearing test).
- Korábbi kezelés
- No cochlear implant in the ear that gets the gene therapy. No investigational drug in a trial in the 6 months before treatment. No earlier gene therapy trial, except AK-OTOF-101 for Part D. Part D is for people already treated in one ear in this trial.
- Biomarker vagy leletérték
- At least two mutations in the otoferlin gene. Preserved distortion product otoacoustic emissions (DPOAEs), a test showing the inner ear's hair cells still respond to sound.
A részvétel fő kizáró okai
- Ear infections that keep coming back
- Abnormal ear structure or other ear problems
- Health problems that rule out surgery, anesthesia or gene therapy
- Cochlear implant in the ear to be treated
- Investigational drug in the past 6 months or any earlier gene therapy trial (except AK-OTOF-101 for Part D)
A regiszter feltételei, szó szerint
Mind a 9 feltétel megnézéseKevesebb
Egyéb feltételek
- Criteria for Inclusion:
- Participants may be of any age, based on Cohort Criteria
- At least two mutations in the otoferlin gene
- Clinical presentation of Profound (Part A) or Severe to Profound (Parts B, C, and D) bilateral sensorineural hearing loss as assessed by ABR
- Preserved distortion product otoacoustic emissions (DPOAEs)
- Able and willing to comply with all study requirements, including willingness to participate in a separate long term follow-up study after completion of this trial; Criteria for Exclusion:
- Persistent ear infections, anatomic or other abnormalities of the ear, and/or medical conditions that would contraindicate undergoing surgery, anesthesia, and/or administration of investigational gene therapy
- Cochlear Implant(s) in the ear(s) to receive AAVAnc80-hOTOF
- Prior participation in a clinical trial with an investigational drug, within six months prior to administration, or any prior participation in a gene therapy clinical trial (with the exception of AK-OTOF-101 for Part D participants)
Helyszínek itt: Kanada
Még 3 másik országban, 8 helyszínen
- Toronto, OntarioHospital not named in the registryContact: Lilly Clinical TrialsNo longer taking part
A vizsgálatról
Mit akar kideríteni a vizsgálat
Part A of this trial evaluated the safety and tolerability of a single surgical administration procedure in one or both ear(s) with one of two dose levels of AAVAnc80-hOTOF (LY888891) and evaluated the Akouos Delivery Device, together with the Precision Delivery Mechanism (as applicable), to safely achieve the intended product performance.
A teljes eredeti leírásKevesebb
Part B of the trial is an open-label, global expansion phase to confirm the efficacy and safety of one dose level of AAVAnc80-hOTOF administered in one or both ear(s). Part B will also evaluate the Intracochlear Delivery System (IDS), which consists of the Akouos Delivery Device, the Precision Delivery Mechanism, and an off-the-shelf syringe.
Part C is a region-specific expansion phase. Part C participants will receive the same dose level of AAVAnc80-hOTOF as participants in Part B, in one or both ear(s) utilizing the IDS.
Part D is a sequential administration phase that allows participants who received AAVAnc80-hOTOF previously in a single ear to receive AAVAnc80-hOTOF administration in the other ear utilizing the IDS.
A vizsgálat 6 csoportja
- Part A: Cohort 1a and Cohort 1bA vizsgált kezelés
Cohort 1a: Two participants aged 7 to 17 years old (inclusive) to receive intracochlear administration of AAVAnc80-hOTOF (dose level 1) in the study ear using a sterile, one-time use investigational medical device Cohort 1b: Up to six eligible participants will be enrolled to receive intracochlear administration of AAVAnc80-hOTOF (dose level 1) in the study ear using a sterile, one-time use investigational medical device; the first three participants will be at least two years of age at the time of AAVAnc80-hOTOF administration and the next three participants may be of any age
Kezelés: AAVAnc80-hOTOF via Akouos Delivery Device
- Part A: Cohort 2A vizsgált kezelés
Cohort 2: Up to six eligible participants will be enrolled to receive intracochlear administration of AAVAnc80-hOTOF (dose level 2) in the study ear using a sterile, one-time use investigational medical device; the first three participants will be at least two years of age at the time of AAVAnc80-hOTOF administration and the next three participants may be of any age
Kezelés: AAVAnc80-hOTOF via Akouos Delivery Device
- Part A: Bilateral ExpansionA vizsgált kezelés
Bilateral Expansion: up to eight eligible participants of any age, and no cochlear implants, may be eligible for enrollment into the Bilateral Expansion Cohort (simultaneous bilateral administration of AAVAnc80-hOTOF).
Kezelés: AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism
- Part BA vizsgált kezelés
Part B: Sixteen participants of any age will be enrolled to receive a single unilateral or bilateral administration of AAVAnc80-hOTOF. Participants with one CI will receive unilateral administration of AAVAnc80-hOTOF, while participants with no CIs will have the choice to receive a unilateral or bilateral administration of AAVAnc80-hOTOF, provided both ears meet eligibility criteria.
Kezelés: AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism
- Part CA vizsgált kezelés
Up to ten eligible participants of any age will be enrolled in a region-specific expansion phase to receive a single unilateral or bilateral administration of AAVAnc80-hOTOF. Participants with one CI will receive unilateral administration of AAVAnc80-hOTOF, while participants with no CIs will have the choice to receive a unilateral or bilateral administration of AAVAnc80-hOTOF, provided both ears meet eligibility criteria.
Kezelés: AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism
- Part DA vizsgált kezelés
Participants of any age may be enrolled into Part D, which is a sequential administration phase that allows participants who received unilateral administration of AAVAnc80-hOTOF in AK-OTOF-101 (Parts A, B, or C) the option to receive dose administration of AAVAnc80-hOTOF in the contralateral ear after completing the Year 1 visit.
Kezelés: AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- A Trial of AAVAnc80-hOTOF Gene Therapy in Individuals With Sensorineural Hearing Loss Due to Otoferlin Gene Mutations
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. szeptember 29.